

# Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

## CAMD

RRID:SCR\_001389

Type: Tool

---

### Proper Citation

CAMD (RRID:SCR\_001389)

---

### Resource Information

**URL:** <http://c-path.org/programs/camd/>

**Proper Citation:** CAMD (RRID:SCR\_001389)

**Description:** THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 8, 2022. Consortium developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases. It is focused on accelerating drug development for patients with chronic neurodegenerative disease, namely, Alzheimer's disease (AD) and Parkinson's disease (PD), by advancing drug development tools for evaluating drug efficacy, conducting clinical trials, and streamlining the process of regulatory review. The consortium focuses on sharing precompetitive patient-level data from the control arms of legacy clinical trials, developing new tools to be submitted to the regulatory agencies, and developing consensus data standards. CAMD has the following areas of focus: (1) qualification of biomarkers, (2) development of common data standards, (3) creation of integrated databases for clinical trials data, and (4) development of quantitative model-based tools for drug development. Regulatory milestones include a qualification opinion with EMA for the use of low baseline hippocampal volume for patient enrichment in pre-dementia trials, and most recently, positive regulatory decisions from the FDA and EMA for the use of a clinical trial simulation tool to aid in trials for mild to moderate stages of AD., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

**Abbreviations:** CAMD

**Synonyms:** Coalition Against Major Diseases

**Resource Type:** data or information resource, portal, consortium, organization portal

**Keywords:** data set, clinical trial, mild cognitive impairment, clinical, biomarker, metadata standard, disease progression model, consortium, drug, data sharing, disease modeling, drug development, disease model, imaging, cerebral spinal fluid

**Funding:** Publicly funded

**Availability:** THIS RESOURCE IS NO LONGER IN SERVICE

**Resource Name:** CAMD

**Resource ID:** SCR\_001389

**Alternate IDs:** nlx\_152563

**Record Creation Time:** 20220129T080207+0000

**Record Last Update:** 20260806T054321+0000

---

## Ratings and Alerts

No rating or validation information has been found for CAMD.

No alerts have been found for CAMD.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Grady K, et al. (2023) Effect of an intervention of exercise on sleep and seizure frequency in idiopathic epileptic dogs. The Journal of small animal practice, 64(2), 59.

Palizhati A, et al. (2022) Agents for sequential learning using multiple-fidelity data. Scientific reports, 12(1), 4694.

Carpio LE, et al. (2021) Computational strategies for the discovery of biological functions of health foods, nutraceuticals and cosmeceuticals: a review. Molecular diversity, 25(3), 1425.

Montoya JH, et al. (2020) Autonomous intelligent agents for accelerated materials discovery. Chemical science, 11(32), 8517.

Neville J, et al. (2017) Accelerating drug development for Alzheimer's disease through the use of data standards. Alzheimer's & dementia (New York, N. Y.), 3(2), 273.

Ribeiro Ede A, et al. (2014) The structure and regulation of human muscle  $\gamma$ -actinin. Cell, 159(6), 1447.